---
title: "Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290573665.md"
description: "Haisco Pharmaceutical Group Co., Ltd. (stock symbol: 002653) based in Beijing shared news on June 23, 2026, regarding an exclusive licensing deal with Nuvectis, a biotech firm in the U.S. This agreement entails various terms and grants Haisco specific rights."
datetime: "2026-06-23T13:20:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290573665.md)
  - [en](https://longbridge.com/en/news/290573665.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290573665.md)
generator: "portal-rs"
---

# Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications

Haisco Pharmaceutical Group Co., Ltd. (stock symbol: 002653) based in Beijing shared news on June 23, 2026, regarding an exclusive licensing deal with Nuvectis, a biotech firm in the U.S. This agreement entails various terms and grants Haisco specific rights.

### Related Stocks

- [002653.CN](https://longbridge.com/en/quote/002653.CN.md)
- [NVCT.US](https://longbridge.com/en/quote/NVCT.US.md)

## Related News & Research

- [China's Haisco Gets China’s Nod for Rare Blood Disorder Drug](https://longbridge.com/en/news/293607538.md)
- [Nuvectis Pharma sets up $200 million at-the-market equity program with Jefferies](https://longbridge.com/en/news/296650648.md)
- [AI isn’t close to curing cancer. This startup says it knows what it will take.](https://longbridge.com/en/news/296352961.md)
- [TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference](https://longbridge.com/en/news/296174254.md)
- [Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate oncology platform, iopofosine I-131 program](https://longbridge.com/en/news/296262041.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**